[Seite 107↓]


1. Henzen C. [Risk factors for arteriosclerosis]. Schweiz Rundsch Med Prax. 2001; 90: 91-5.

2. Frohlich J, Dobiasova M, Lear S, Lee KW. The role of risk factors in the development of atherosclerosis. Crit Rev Clin Lab Sci. 2001; 38: 401-40.

3. Simon AC, Levenson JA, Safar ME. Systolic hypertension: differences of mechanism according to age and possible application to treatment. Eur Heart J. 1982; 3 Suppl C: 65-9.

4. Ferdinand KC. Update in pharmacologic treatment of hypertension. Cardiol Clin. 2001; 19: 279-94, v.

5. Leopold JA, Loscalzo J. Clinical importance of understanding vascular biology. Cardiol Rev. 2000; 8: 115-23.

6. Frohlich ED. Hypertension: our major challenges. Hypertension. 2001; 38: 990-1.

7. Bohm M, Castellano M, Agabiti-Rosei E, Flesch M, Paul M, Erdmann E. Dose-dependent dissociation of ACE-inhibitor effects on blood pressure, cardiac hypertrophy, and beta-adrenergic signal transduction. Circulation. 1995; 92: 3006-13.

8. Frankel DH. Mechanism-based medicine proposed for hypertension. Lancet. 1996; 347: 1473.

9. Smith D. Cardiovascular disease: a historic perspective. Jpn J Vet Res. 2000; 48: 147-66.

10. Savage DD, Watkins LO, McGee DL. A mechanism for the development of fixed primary (essential) hypertension: insights from population-based studies using echocardiography. Clin Cardiol. 1989; 12: IV23-9.

11. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci. 2002; 323: 17-24.

12. Hanke H, Lenz C, Finking G. The discovery of the pathophysiological aspects of atherosclerosis--a review. Acta Chir Belg. 2001; 101: 162-9.

13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-9.

14. Dzau VJ. Mechanism of the interaction of hypertension and hypercholesterolemia in atherogenesis: the effects of antihypertensive agents. Am Heart J. 1988; 116: 1725-8.

15. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol. 1997; 62 Suppl 2: S23-9.

16. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002; 66: 529-33.

17. Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in coronary artery disease. Haemostasis. 1997; 27 Suppl 1: 12-8.

[Seite 108↓]

18. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996; 7: 330-5.

19. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? [editorial; comment]. Circulation. 1998; 97: 1671-4.

20. Aviram M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxid Redox Signal. 1999; 1: 585-94.

21. Nickenig G, Strehlow K, Baumer AT, Baudler S, Wassmann S, Sauer H, Bohm M. Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol. 2000; 131: 795-803.

22. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993; 143: 987-1002.

23. Crea F, Biasucci LM, Buffon A, Liuzzo G, Monaco C, Caligiuri G, Kol A, Sperti G, Cianflone D, Maseri A. Role of inflammation in the pathogenesis of unstable coronary artery disease. Am J Cardiol. 1997; 80: 10e-16e.

24. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep. 2002; 4: 92-8.

25. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995; 25 Suppl 2: S9-12.

26. Tegos TJ, Kalodiki E, Sabetai MM, Nicolaides AN. The genesis of atherosclerosis and risk factors: a review. Angiology. 2001; 52: 89-98.

27. Najemnik C, Sinzinger H, Kritz H. Endothelial dysfunction, atherosclerosis and diabetes. Acta Med Austriaca. 1999; 26: 148-53.

28. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994; 24: 1591-601.

29. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340: 115-26.

30. DiMario JX. Activation and repression of growth factor receptor gene transcription (Review). Int J Mol Med. 2002; 10: 65-71.

31. Barton M, Haudenschild CC. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol. 2001; 38 Suppl 2: S23-5.

32. Regitz-Zagrosek V, Auch-Schwelk W, Hess B, Klein U, Duske E, Steffen C, Hildebrandt AG, Fleck E. Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol. 1995; 26: 66-72.

33. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol. 2001; 88: 3J-6J.

34. Kolloch RE. [Hypertension 2001]. Dtsch Med Wochenschr. 2001; 126: 1321.

[Seite 109↓]

35. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol. 2001; 88: 1L-20L.

36. Colwell J. Pathogenesis of vascular disease. Diabetes Obes Metab. 2000; 2 Suppl 2: S19-24.

37. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res. 1997; 81: 970-6.

38. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000; 20: E83-8.

39. Moreno PR, Bernardi VH, Lopez Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996; 94: 3090-7.

40. Coste P. [Atherosclerosis. Pathologic anatomy, physiopathology, epidemiology and risk factors, prevention]. Rev Prat. 2001; 51: 85-91.

41. Gavornik P, Galbavy S. Clinical picture of arteriolosclerosis. Bratisl Lek Listy. 2001; 102: 326-31.

42. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts [see comments]. Am J Obstet Gynecol. 1998; 179: 1359-75.

43. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension [published erratum appears in Lancet 1993 Aug 21; 342(8869): 504] [see comments]. Lancet. 1993; 341: 1447-51.

44. Norwitz ER, Repke JT. Preeclampsia prevention and management. J Soc Gynecol Investig. 2000; 7: 21-36.

45. VanWijk MJ, Kublickiene K, Boer K, VanBavel E. Vascular function in preeclampsia. Cardiovasc Res. 2000; 47: 38-48.

46. Morgan T, Ward K. New insights into the genetics of preeclampsia. Semin-Perinatol. 1999; 23: 14-23.

47. Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet-Gynecol-Surv. 1998; 53: 377-82.

48. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, MacPherson C, Landon M, Miodovnik M, Paul R, Meis P, Dombrowski M. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N-Engl-J-Med. 1998; 339: 667-71.

[Seite 110↓]

49. Burley SK, Kamada K. Transcription factor complexes. Curr Opin Struct Biol. 2002; 12: 225-30.

50. Scheidereit C. Transcription factors: important tools and targets for molecular medicine. J Mol Med. 1996; 74: 707-9.

51. Emery JG, Ohlstein EH, Jaye M. Therapeutic modulation of transcription factor activity. Trends Pharmacol Sci. 2001; 22: 233-40.

52. Stenoien DL, Simeoni S, Sharp ZD, Mancini MA. Subnuclear dynamics and transcription factor function. J Cell Biochem Suppl. 2000; Suppl 35: 99-106.

53. Liou HC, Baltimore D. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol. 1993; 5: 477-87.

54. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription [see comments]. Faseb J. 1996; 10: 709-20.

55. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12: 141-79.

56. Choi M, Rolle S, Wellner M, Cardoso MC, Scheidereit C, Luft FC, Kettritz R. Inhibition of NF-{kappa}B by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. Blood. 2003.

57. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene. 1997; 14: 2899-916.

58. Baldwin AS, Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001; 107: 3-6.

59. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol. 1999; 19: 6367-78.

60. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995; 80: 529-32.

61. Renard P, Raes M. The proinflammatory transcription factor NFkappaB: a potential target for novel therapeutical strategies. Cell Biol Toxicol. 1999; 15: 341-4.

62. Ginn Pease ME, Whisler RL. Redox signals and NF-kappaB activation in T cells. Free Radic Biol Med. 1998; 25: 346-61.

63. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996; 87: 13-20.

64. May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol. 1997; 8: 63-73.

65. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14: 649-83.

66. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control [comment]. Cell. 1998; 95: 729-31.

[Seite 111↓]

67. Huguet C, Crepieux P, Laudet V. Rel/NF-kappa B transcription factors and I kappa B inhibitors: evolution from a unique common ancestor. Oncogene. 1997; 15: 2965-74.

68. Bours V, Villalobos J, Burd PR, Kelly K, Siebenlist U. Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature. 1990; 348: 76-80.

69. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol. 2000; 12: 52-8.

70. Simeonidis S, Stauber D, Chen G, Hendrickson WA, Thanos D. Mechanisms by which IkappaB proteins control NF-kappaB activity. Proc Natl Acad Sci U S A. 1999; 96: 49-54.

71. Scheidereit C. Signal transduction. Docking IkappaB kinases [news; comment]. Nature. 1998; 395: 225-6.

72. Tran K, Merika M, Thanos D. Distinct functional properties of IkappaB alpha and IkappaB beta. Mol Cell Biol. 1997; 17: 5386-99.

73. Naumann M, Scheidereit C. Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. Embo J. 1994; 13: 4597-607.

74. Naumann M, Wulczyn FG, Scheidereit C. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B. Embo J. 1993; 12: 213-22.

75. Rice NR, Ernst MK. In vivo control of NF-kappa B activation by I kappa B alpha. Embo J. 1993; 12: 4685-95.

76. Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA, Scheidereit C. The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. J Biol Chem. 2000; 275: 29779-87.

77. Akira S, Kishimoto T. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol. 1997; 65: 1-46.

78. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. Faseb J. 1995; 9: 899-909.

79. Nichols TC, Fischer TH, Deliargyris EN, Baldwin AS, Jr. Role of nuclear factor-kappa B (NF-kappa B) in inflammation, periodontitis, and atherogenesis. Ann Periodontol. 2001; 6: 20-9.

80. Wulczyn FG, Krappmann D, Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med. 1996; 74: 749-69.

81. van den Berg R, Haenen GR, van den Berg H, Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br J Nutr. 2001; 86 Suppl 1: S121-7.

82. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001; 107: 255-64.

[Seite 112↓]

83. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997; 82: 297-304.

84. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor- kappaB binding site prevents myocardial infarction [see comments]. Nat Med. 1997; 3: 894-9.

85. Ritchie ME. Nuclear Factor-kappa B is selectively and markedly activated in Humans with Unstable Angina Pectoris. Circulation. 1998; 98: 1707-1713.

86. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996; 97: 1715-22.

87. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95: 1532-41.

88. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 1994; 94: 877-84.

89. Muller DN, Dechend R, Fiebeler A, Park JK, Haller H, Luft FC. Angiotensin-induced inflammation and novel approaches to treatment. Adv Nephrol Necker Hosp. 2001; 31: 89-103.

90. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 1997; 65: 111-37.

91. Guo S, Wang W, Zhai Y. [Research progression of nuclear transcription factor-kappaB]. Zhonghua Bing Li Xue Za Zhi. 2000; 29: 379-80.

92. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int. 2001; 59: 415-24.

93. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000; 35: 193-201.

94. Muraoka K, Shimizu K, Sun X, Zhang YK, Tani T, Hashimoto T, Yagi M, Miyazaki I, Yamamoto K. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation. 1997; 63: 466-70.

95. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene. 1999; 18: 7423-31.

[Seite 113↓]

96. Soares MP, Muniappan A, Kaczmarek E, Koziak K, Wrighton CJ, Steinhauslin F, Ferran C, Winkler H, Bach FH, Anrather J. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. J Immunol. 1998; 161: 4572-82.

97. Scheidereit C. Transcription factors: important tools and targets for molecular medicine [editorial]. J Mol Med. 1996; 74: 707-9.

98. Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A, Shagdarsuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. Faseb J. 2001; 15: 1822-4.

99. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000; 1470: M55-62.

100. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001; 107: 241-6.

101. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999; 18: 943-53.

102. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dorken B, Zenke M, Stein H, Scheidereit C. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002; 196: 605-17.

103. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. High-level expression of BCL3 differentiates t(2; 5)(p23; q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood. 2003; 101: 2789-96.

104. Schmidt-Ullrich R, Aebischer T, Hulsken J, Birchmeier W, Klemm U, Scheidereit C. Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices. Development. 2001; 128: 3843-53.

105. Giuliani C, Napolitano G, Bucci I, Montani V, Monaco F. [Nf-kB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications]. Clin Ter. 2001; 152: 249-53.

106. Inoue J, Takahara T, Akizawa T, Hino O. Bcl-3, a member of the I kappa B proteins, has distinct specificity towards the Rel family of proteins. Oncogene. 1993; 8: 2067-73.

107. Kerr LD, Duckett CS, Wamsley P, Zhang Q, Chiao P, Nabel G, McKeithan TW, Baeuerle PA, Verma IM. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev. 1992; 6: 2352-63.

[Seite 114↓]

108. Hatada EN, Nieters A, Wulczyn FG, Naumann M, Meyer R, Nucifora G, McKeithan TW, Scheidereit C. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc Natl Acad Sci U S A. 1992; 89: 2489-93.

109. Michel F, Soler-Lopez M, Petosa C, Cramer P, Siebenlist U, Muller CW. Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family. Embo J. 2001; 20: 6180-90.

110. Lenardo M, Siebenlist U. Bcl-3-mediated nuclear regulation of the NF-kappa B trans-activating factor. Immunol Today. 1994; 15: 145-7.

111. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993; 7: 1354-63.

112. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature. 1992; 359: 339-42.

113. Watanabe N, Iwamura T, Shinoda T, Fujita T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. Embo J. 1997; 16: 3609-20.

114. Brasier AR, Lu M, Hai T, Lu Y, Boldogh I. NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. J Biol Chem. 2001; 276: 32080-93.

115. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. Embo J. 1999; 18: 4766-78.

116. Caamano JH, Perez P, Lira SA, Bravo R. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol. 1996; 16: 1342-8.

117. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993; 72: 729-39.

118. Guan E, Wang J, Laborda J, Norcross M, Baeuerle PA, Hoffman T. T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J Exp Med. 1996; 183: 2025-32.

119. Pan J, McEver RP. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-kappa B/Rel family. J Biol Chem. 1995; 270: 23077-83.

120. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol. 2002; 71: 9-15.

[Seite 115↓]

121. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [see comments] [published erratum appears in N Engl J Med 1997 Jul 31; 337(5): 356]. N Engl J Med. 1997; 336: 973-9.

122. Mlot C. Chlamydia linked to atherosclerosis [news]. Science. 1996; 272: 1422.

123. Marrie TJ. Chlamydia pneumoniae [editorial]. Thorax. 1993; 48: 1-4.

124. Gibbs RG, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg. 1998; 85: 1191-7.

125. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, Strandness ED, Wang SP. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery [see comments]. Circulation. 1995; 92: 3397-400.

126. Gupta S, Leatham EW. The relation between Chlamydia pneumoniae and atherosclerosis [editorial]. Heart. 1997; 77: 7-8.

127. Bartels C, Maass M, Bein B, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998; 31: 827-831.

128. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM, Leinonen M, Kairaluoma MI, Saikku P. Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms. Ann N Y Acad Sci. 1996; 800: 236-8.

129. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, Grayston JT. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997; 150: 1785-90.

130. Saikku P. Chlamydia pneumoniae and atherosclerosis--an update. Scand J Infect Dis Suppl. 1997; 104: 53-6.

131. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol. 1996; 49: 102-6.

132. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998; 97: 633-6.

133. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, Woods ML, Anderson JL. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996; 27: 1555-61.

134. Taylor Robinson D. Chlamydia pneumoniae infection and coronary heart disease. Trials should assess whether antibiotics eliminate organism from atherosclerotic lesions [letter]. Bmj. 1997; 315: 1538.

[Seite 116↓]

135. Numazaki K, Chiba S. Chlamydia pneumoniae infection and coronary heart disease. Role of C pneumoniae in pathogenesis of atherosclerosis must be determined [letter]. Bmj. 1997; 315: 1538.

136. Maass M, Krause E, Engel PM, Kruger S. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology. 1997; 48: 699-706.

137. Shor A. Mechanism of Arterial Infection by Chlamydia pneumoniae. Circulation. 2001; 104: E75.

138. Mahony JB, Coombes BK. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? FEMS Microbiol Lett. 2001; 197: 1-9.

139. Streblow DN, Orloff SL, Nelson JA. Do pathogens accelerate atherosclerosis? J Nutr. 2001; 131: 2798S-2804S.

140. Girard SE, Temesgen Z. Emerging concepts in disease management: a role for antimicrobial therapy in coronary artery disease. Expert Opin Pharmacother. 2001; 2: 765-72.

141. Gabrielli M, Santarelli L, Gasbarrini A. Chlamydia pneumoniae infection: which role in atherosclerosis? Arch Intern Med. 2002; 162: 2140; author reply 2141.

142. Ngeh J, Gupta S. Inflammation, infection and antimicrobial therapy in coronary heart disease--where do we currently stand? Fundam Clin Pharmacol. 2001; 15: 85-93.

143. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997; 96: 4095-103.

144. Dugan JP, Feuge RR, Burgess DS. Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Clin Ther. 2002; 24: 719-35.

145. Yla Herttuala S. Gene expression in atherosclerotic lesions. Herz. 1992; 17: 270-6.

146. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001; 103: 351-6.

147. Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI. Am Heart J. 1999; 138: 177-82.

148. Leowattana W. Chronic infections and atherosclerosis. J Med Assoc Thai. 2001; 84 Suppl 3: S650-7.

149. Riccioni G, De Santis A, Cerasa V, Menna V, Di Ilio C, Schiavone C, Ballone E, D'Orazio N. Atherosclerotic plaque formation and risk factors. Int J Immunopathol Pharmacol. 2003; 16: 25-31.

150. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002; 53: 911-20.

151. Phillips JI, Shor A. Association between Chlamydia pneumoniae and atherosclerotic lesions. Cardiovasc J S Afr. 2001; 12: 42-6.

[Seite 117↓]

152. Gabay MP, Jain R. Role of antibiotics for the prevention of cardiovascular disease. Ann Pharmacother. 2002; 36: 1629-36.

153. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI- 1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999; 100: 1369-73.

154. Grayston JT. Chlamydia pneumoniae and atherosclerosis. Rev Med Interne. 1996; 17 Suppl 1: 45s-47s.

155. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998; 177: 725-9.

156. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994; 6: 87-91.

157. Liu L, Hu H, Ji H, Murdin AD, Pierce GN, Zhong G. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Mol Cell Biochem. 2000; 215: 123-8.

158. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998; 98: 300-7.

159. Peeling RW, Brunham RC. Chlamydiae as pathogens: new species and new issues. Emerg Infect Dis. 1996; 2: 307-19.

160. Scholze J, Dominiak P. [Therapy of hypertension between claims and reality]. Fortschr Med. 1996; 114: 26-8.

161. Doyle AE. Autonomic and vascular mechanism in hypertension. Singapore Med J. 1973; 14: 391-2.

162. Dzau VJ. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. Drugs. 1990; 39 Suppl 2: 11-6.

163. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001; 37: 1047-52.

164. Inagaki K, Iwanaga Y, Sarai N, Onozawa Y, Takenaka H, Mochly-Rosen D, Kihara Y. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC varepsilon and PKCbeta. J Mol Cell Cardiol. 2002; 34: 1377-85.

165. Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol. 2001; 16: 317-27.

166. Gross V, Lippoldt A, Bohlender J, Ganten D, Ganten U, Luft FC. The renin-angiotensin system and renal function in transgenic (mRen2)27 rats. Exp Nephrol. 1996; 4 Suppl 1: 20-6.

167. Bader M, Ganten D. Transgenic rats: tools to study the function of the renin-angiotensin system. Clin Exp Pharmacol Physiol Suppl. 1996; 3: S81-7.

[Seite 118↓]

168. Wagner J, Thiele F, Ganten D. The renin-angiotensin system in transgenic rats. Pediatr Nephrol. 1996; 10: 108-12.

169. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med. 2001; 79: 76-102.

170. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999; 33: 389-95.

171. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage : A new transgenic approach to an old problem. Hypertension. 1999; 33: 212-8.

172. Muller DN, Dechend R, Fiebeler A, Park JK, Haller H, Luft FC. Angiotensin-induced inflammation and vascular injury. Contrib Nephrol. 2001: 138-52.

173. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation. 1994; 89: 493-8.

174. Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension. 2000; 35: 587-94.

175. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Loffler BM, Ganten D, Schneider W, Haller H, Luft FC. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000; 36: 282-90.

176. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider W, Gulba D, Ganten D, Haller H, Luft FC. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol. 2000; 157: 111-22.

177. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Muller DN, Fiebeler A, Ganten U, Ganten D, Luft FC. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension. 2001; 37: 414-8.

178. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider W, Gulba D, Ganten D, Haller H, Luft FC. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy [In Process Citation]. Am J Pathol. 2000; 157: 111-22.

179. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002; 2: 3.

180. Osterud B. Tissue factor: a complex biological role. Thromb Haemost. 1997; 78: 755-8.

[Seite 119↓]

181. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler BM, Blum-Kaelin D, Masur S, Dehmlow H, Aebi JD, Haller H, Luft FC. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension. 2002; 40: 840-6.

182. Mervaala E, Muller DN, Park JK, Dechend R, Schmidt F, Fiebeler A, Bieringer M, Breu V, Ganten D, Haller H, Luft FC. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension. 2000; 35: 360-6.

183. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002; 161: 1679-93.

184. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998; 396: 77-80.

185. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98: 839-44.

186. Zucchelli P, Zuccala A. The kidney as a victim of essential hypertension. J Nephrol. 1997; 10: 203-6.

187. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol. 1988; 255: F563-73.

188. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999; 12: 205S-213S.

189. Wintroub BU, Klickstein LB, Dzau VJ, Watt KW. Granulocyte-angiotensin system. Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry. 1984; 23: 227-32.

190. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol. 1999; 33: S21-8; discussion S41-3.

191. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep. 2003; 5: 73-9.

192. Unger T, Azizi M, Belz GG. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. J Hum Hypertens. 2000; 14 Suppl 2: S23-31.

193. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991; 17: 626-35.

194. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension. 1998; 31: 1324-30.

[Seite 120↓]

195. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension. 2001; 37: 787-93.

196. Park JK, Fiebeler A, Muller DN, Mervaala EM, Dechend R, Abou-Rebyeh F, Luft FC, Haller H. Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension. 2002; 39: 685-9.

197. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000; 58: 1420-30.

198. Brasier AR, Recinos A, 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22: 1257-66.

199. Jobin C, Sartor RB. The IkappaB/NF-kappaB system: a key determinant of mucosal inflammation and protection [In Process Citation]. Am J Physiol Cell Physiol. 2000; 278: C451-62.

200. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J. Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant. 2001; 16 Suppl 1: 27-33.

201. Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, Maass M. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation. 2003; 108: 261-5.

202. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 1997; 29: 366-73.

203. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 2002; 91: 406-13.

204. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases. Curr Drug Targets. 2003; 4: 339-46.

205. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003; 35: 881-900.

206. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 2000; 57: 2285-98.

207. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998; 339: 1448-56.

208. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996; 156: 3961-9.

[Seite 121↓]

209. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994; 265: 956-9.

210. Chesley LC. Hypertension in pregnancy: definitions, familial factor, and remote prognosis. Kidney Int. 1980; 18: 234-40.

211. Lindheimer MD. Pre-eclampsia-eclampsia 1996: preventable? Have disputes on its treatment been resolved? Curr-Opin-Nephrol-Hypertens. 1996; 5: 452-8.

212. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998; 179: 1359-75.

213. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension. 2003; 41: 437-45.

214. Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol. 1999; 42: 422-35.

215. Redman CW, Roberts JM. Management of pre-eclampsia. Lancet. 1993; 341: 1451-4.

216. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003; 101: 1319-32.

217. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol. 2000; 24: 24-8.

218. Morgan L, Baker P, Pipkin FB, Kalsheker N. Pre-eclampsia and the angiotensinogen gene. Br-J-Obstet-Gynaecol. 1995; 102: 489-90.

219. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991; 98: 648-55.

220. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? [see comments]. J-Clin-Invest. 1997; 99: 2152-64.

221. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002; 9: 147-60.

222. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am-J-Hypertens. 1991; 4: 700-8.

223. Myatt L. Role of placenta in preeclampsia. Endocrine. 2002; 19: 103-11.

224. Kuller JA, D'Andrea NM, McMahon MJ. Renal biopsy and pregnancy. Am J Obstet Gynecol. 2001; 184: 1093-6.

225. Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres-Clin-Obstet-Gynaecol. 1994; 8: 443-68.

[Seite 122↓]

226. van Beek E, Ekhart TH, Schiffers PM, van Eyck J, Peeters LL, de Leeuw PW. Persistent abnormalities in plasma volume and renal hemodynamics in patients with a history of preeclampsia. Am-J-Obstet-Gynecol. 1998; 179: 690-6.

227. Pridjian G, Puschett JB. Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv. 2002; 57: 619-40.

228. Wilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv. 2003; 58: 39-66.

229. Morgan T, Craven C, Lalouel JM, Ward K. Angiotensinogen Thr235 variant is associated with abnormal physiologic change of the uterine spiral arteries in first-trimester decidua. Am-J-Obstet-Gynecol. 1999; 180: 95-102.

230. Vinatier D, Monnier JC. Pre-eclampsia: physiology and immunological aspects [see comments]. Eur-J-Obstet-Gynecol-Reprod-Biol. 1995; 61: 85-97.

231. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? [see comments]. J-Clin-Invest. 1997; 99: 2139-51.

232. Austgulen R, Lien E, Vince G, Redman CW. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 1997; 71: 53-8.

233. Morgan T, Craven C, Ward K. Human spiral artery renin-angiotensin system. Hypertension. 1998; 32: 683-7.

234. Gaunt G, Ramin K. Immunological tolerance of the human fetus. Am J Perinatol. 2001; 18: 299-312.

235. Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv. 1998; 53: 377-82.

236. Roberts JM. Angiotensin-1 receptor autoantibodies: A role in the pathogenesis of preeclampsia? [editorial; comment]. Circulation. 2000; 101: 2335-7.

237. Waite LL, Atwood AK, Taylor RN. Preeclampsia, an implantation disorder. Rev Endocr Metab Disord. 2002; 3: 151-8.

238. Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. J Perinat Med. 1996; 24: 99-117.

239. Haller H, Ziegler EM, Homuth V, Drab M, Eichhorn J, Nagy Z, Busjahn A, Vetter K, Luft FC. Endothelial adhesion molecules and leukocyte integrins in preeclamptic patients. Hypertension. 1997; 29: 291-6.

240. Haller H, Hempel A, Homuth V, Mandelkow A, Busjahn A, Maasch C, Drab M, Lindschau C, Jupner A, Vetter K, Dudenhausen J, Luft FC. Endothelial-cell permeability and protein kinase C in pre-eclampsia. Lancet. 1998; 351: 945-9.

241. Dekker GA, Sibai BM. The immunology of preeclampsia. Semin Perinatol. 1999; 23: 24-33.

[Seite 123↓]

242. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J-Clin-Invest. 1999; 103: 945-52.

243. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999; 6: 342-8.

244. Baker PN, Kilby MD, Pipkin FB. Angiotensin II-induced increases in platelet intracellular free calcium in hypertensive and normotensive pregnancy [letter; comment]. Am-J-Obstet-Gynecol. 1993; 169: 749-50.

245. Regitz-Zagrosek V, Neuss M, Holzmeister J, Warnecke C, Fleck E. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. J Mol Med. 1996; 74: 233-51.

246. Baker PN, Broughton Pipkin F, Symonds EM. Platelet angiotensin II binding sites in normotensive and hypertensive women. Br-J-Obstet-Gynaecol. 1991; 98: 436-40.

247. Bes A, Corvol P, Dzau VJ, Fillastre JP, Lekieffre J, Passa P, Vasmant D, Waeber B, Zanchetti A. Circulating and tissue renin-angiotensin system: present and future. J Cardiovasc Pharmacol. 1989; 14 Suppl 4: S60-65.

248. Dimmeler S, Zeiher AM. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept. 2000; 90: 19-25.

249. Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 2002; 23: 359-72.

250. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357: 53-6.

251. Leung PS, Tsai SJ, Wallukat G, Leung TN, Lau TK. The upregulation of angiotensin II receptor AT(1) in human preeclamptic placenta. Mol Cell Endocrinol. 2001; 184: 95-102.

252. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension. 1997; 29: 678-82.

253. Wallukat G, Nissen E. Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods. In Vitro Cell Dev Biol Anim. 2001; 37: 175-6.

254. Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallukat G, Wernecke KD, Stangl K, Baumann G, Felix SB. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001; 103: 2681-6.

255. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab. 2001; 86: 2505-12.

256. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998; 16: 5-15.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: